Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Yervoy (Ipilimumab) for Cancer: What Patients Need to Know
Yervoy (Ipilimumab) for Cancer: What Patients Need to Know. Learn how Yervoy (ipilimumab) works, which cancers it treats, common side effects, immune-related complications, and evidence-based integrative therapies that may help.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage cancer is to combine the best of conventional and evidence-based non-conventional therapies.
I have come to believe that therapy-induced side effects can be life-threatening while ruining quality of life. Consider therapies shown to reduce possible side effects.
Before beginning Yervoy (Ipilimumab) for Cancer, consider:
Scroll down the page and post a question or a comment if there’s anything you’d like to know about carboplatin + paclitaxel for cancer.
Good luck,
David Emerson
Concepts Central to Managing Your Cancer-
- Integrative Oncology: Combining Conventional and Natural Cancer Therapies
- Complementary Cancer Therapies: Evidence-based
- Immunotherapy for Cancer: What Patients Need to Know Before, During, and After Treatment
- Managing Cancer Treatment Side Effects: An Evidence-Based Guide to Prevention, Relief, and Recovery
- Cancer Financial Toxicity: Costs, Medical Debt, Insurance, Financial Assistance, and Survivorship
Yervoy (Ipilimumab) for Cancer: What Patients Need to Know
Yervoy (ipilimumab) was the first immune checkpoint inhibitor shown to help some patients with advanced cancer live for many years. Before its approval in 2011, metastatic melanoma was almost always fatal. Yervoy changed that by demonstrating that activating the immune system could produce durable responses—even after treatment ended.
Today, Yervoy is used alone for some patients but more commonly in combination with Opdivo (nivolumab) because the two drugs stimulate different parts of the immune system.
Unlike chemotherapy, Yervoy does not kill cancer cells directly.
Instead, it removes one of the immune system’s “brakes,” allowing T-cells to recognize and attack cancer.
For some patients this leads to remarkable, long-lasting remissions.
For others, however, activating the immune system can also cause it to attack healthy organs.
Understanding both the benefits and risks is essential.
Quick Facts
| Generic name | Ipilimumab |
|---|---|
| Brand name | Yervoy |
| Drug class | CTLA-4 immune checkpoint inhibitor |
| Administration | Intravenous infusion |
| Common schedule | Every 3 weeks for four doses (varies by cancer) |
| FDA approval | 2011 |
| Often combined with | Opdivo (nivolumab) |
What is Yervoy?
Yervoy is a monoclonal antibody that blocks CTLA-4, an immune checkpoint protein found on T-cells.
Normally, CTLA-4 prevents excessive immune activation.
Cancer takes advantage of this protective mechanism.
Blocking CTLA-4 allows T-cells to become more active against tumors.
How Yervoy Works
Think of your immune system as a car.
- Accelerator = immune activation
- Brakes = immune checkpoints
- Cancer pushes harder on the brakes.
Yervoy releases one of those brakes.
Unlike chemotherapy:
- It doesn’t poison cancer cells.
- It trains your immune system.
- Responses can continue long after treatment has ended.
Yervoy vs. Opdivo
| Yervoy | Opdivo |
|---|---|
| Targets CTLA-4 | Targets PD-1 |
| Works early during T-cell activation | Works later inside the tumor |
| More immune activation | Less generalized activation |
| Higher risk of immune side effects | Generally better tolerated |
| Frequently combined with Opdivo | Often continued after Yervoy ends |
One way to explain the combination:
Yervoy recruits and activates immune cells. Opdivo keeps them working once they reach the tumor.
This complementary mechanism is why the combination is more effective for many cancers, although it also increases immune-related toxicity.
Which Cancers is Yervoy Used to Treat?
Depending on the clinical situation, Yervoy may be used for:
- Melanoma
- Kidney cancer (renal cell carcinoma)
- Colorectal cancer with MSI-H/dMMR
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Pleural mesothelioma
- Esophageal squamous cell carcinoma
Most modern uses involve combination therapy with nivolumab. Approved indications continue to expand.
Common Side Effects
Unlike chemotherapy, Yervoy side effects result from an overactive immune system.
Common
- Fatigue
- Rash
- Itching
- Diarrhea
- Nausea
- Decreased appetite
- Fever
Less Common
- Joint pain
- Headache
- Infusion reactions
Serious Immune-Related Side Effects
These deserve an entire section because they distinguish immunotherapy from chemotherapy.
Yervoy can cause inflammation in almost any organ.
Gastrointestinal
- Colitis
- Severe diarrhea
- Bowel perforation (rare)
Liver
- Hepatitis
- Elevated liver enzymes
Endocrine
- Thyroiditis
- Hypothyroidism
- Hyperthyroidism
- Hypophysitis
- Adrenal insufficiency
- Diabetes
Lung
- Pneumonitis
Skin
- Severe rash
- Stevens-Johnson syndrome (rare)
Kidney
- Nephritis
Heart
- Myocarditis (rare)
Nervous system
- Neuropathy
- Myasthenia gravis
- Guillain-Barré syndrome (rare)
Patients should report new diarrhea, shortness of breath, severe fatigue, vision changes, persistent headache, jaundice, or weakness immediately, since early corticosteroid treatment often prevents more serious complications.
Integrative Therapies That May Help
These therapies do not replace immunotherapy, but they may help patients tolerate treatment better or improve overall quality of life.
| Therapy | Evidence | Goal |
|---|---|---|
| Exercise | Strong | Reduce fatigue |
| Mediterranean diet | Strong | Lower systemic inflammation |
| High-protein nutrition | Strong | Preserve muscle |
| Sleep optimization | Moderate | Immune recovery |
| Mindfulness | Moderate | Reduce anxiety |
| Acupuncture | Moderate | Pain management |
| Vitamin D (if deficient) | Moderate | Correct deficiency |
| Omega-3 fats | Moderate | Support overall health |
Supplements Requiring Caution
Like chemotherapy, patients receiving checkpoint inhibitors should always discuss supplements with their oncology team.
Some supplements theoretically alter immune activity.
Extra caution is warranted with:
- High-dose antioxidants
- High-dose curcumin
- Medicinal mushrooms
- Astragalus
- Immune-stimulating herbal blends
The evidence is limited, but timing and dosing should be individualized.
Nutrition During Treatment
Most experts recommend:
- Adequate protein
- Fruits
- Vegetables
- Whole grains
- Healthy fats
- Good hydration
Avoid unnecessary restrictive diets unless recommended by your medical team.
Questions to Ask Your Oncologist
- Why are you recommending Yervoy?
- Will I receive Opdivo with it?
- What immune-related side effects should I watch for?
- How often will my blood work be checked?
- When should I call after hours?
- Which symptoms require emergency evaluation?
- Can I continue my supplements?
- How long will treatment continue?
Evidence Rating
| Topic | Evidence |
|---|---|
| Yervoy improves survival in melanoma | ★★★★★ |
| Combination Yervoy + Opdivo | ★★★★★ |
| Exercise reduces cancer fatigue | ★★★★★ |
| Mediterranean diet benefits survivors | ★★★★☆ |
| Mindfulness for anxiety | ★★★★☆ |
| Acupuncture for symptom management | ★★★★☆ |
| High-dose supplements during immunotherapy | ★★☆☆☆ |
Why Does Yervoy Cause More Side Effects Than Opdivo?
One of the most common questions patients ask is:
“If both Yervoy and Opdivo help my immune system fight cancer, why does Yervoy usually cause more side effects?”
The answer lies in where each drug acts in the immune response.
Think of your immune system as an army.
Before soldiers are sent into battle, they first gather at a training camp where commanders decide whether to activate them.
After they leave training, they travel to the battlefield to attack the enemy.
Yervoy Acts at the “Training Camp”
Yervoy blocks a protein called CTLA-4, one of the immune system’s earliest checkpoints.
CTLA-4 normally prevents T-cells from becoming overly activated.
When Yervoy blocks CTLA-4, many more T-cells become activated throughout the body, not just those near the tumor.
This broad immune activation gives the immune system more cancer-fighting power—but it also increases the likelihood that healthy organs become unintended targets.
That is why Yervoy is associated with relatively high rates of:
- Colitis
- Hepatitis
- Thyroid disorders
- Pituitary inflammation (hypophysitis)
- Skin rashes
- Severe diarrhea
- Other immune-related adverse events
Opdivo Acts at the “Battlefield”
Opdivo works differently.
Instead of activating large numbers of new immune cells, it blocks the PD-1 checkpoint, which cancer cells use to “hide” from already activated T-cells.
PD-1 functions mainly inside and around the tumor after T-cells have already been activated.
Rather than recruiting a larger immune army, Opdivo helps existing immune cells recognize cancer cells that were previously escaping detection.
Because this effect is more targeted, Opdivo generally causes fewer serious immune-related side effects than Yervoy, although significant complications can still occur.
Why the Combination Works So Well
If Yervoy activates new T-cells and Opdivo keeps those T-cells attacking the cancer, combining the two drugs can produce a stronger anti-cancer immune response than either medication alone.
Many oncologists describe the partnership like this:
| Yervoy | Opdivo |
|---|---|
| Recruits more immune soldiers | Keeps the soldiers fighting |
| Starts the immune response | Sustains the immune response |
| Acts early in lymph nodes | Acts later within the tumor |
| Stronger immune activation | More targeted immune activation |
| More side effects | Usually fewer side effects |
This complementary approach has improved survival for many patients with advanced melanoma, kidney cancer, mesothelioma, liver cancer, and several other cancers.
The trade-off is that combination therapy also increases the risk of immune-related side effects, making careful monitoring essential throughout treatment.
Why Early Reporting of Symptoms Matters
Unlike chemotherapy side effects, immune-related side effects often become much easier to treat when recognized early.
A mild rash, persistent diarrhea, worsening fatigue, or a new headache may seem minor at first, but these symptoms can be the earliest signs that the immune system is attacking healthy organs.
Many immune-related side effects improve with prompt treatment—often temporary corticosteroids and, if necessary, pausing immunotherapy. Delaying treatment, however, can allow inflammation to become more severe and, in rare cases, life-threatening.
Never assume that a new symptom is “just part of treatment.” Contact your oncology team promptly if you develop:
- Diarrhea lasting more than a day or two
- Bloody stools
- Yellowing of the skin or eyes
- Persistent cough or shortness of breath
- Severe fatigue or dizziness
- Vision changes
- New severe headaches
- Confusion
- Chest pain
- Muscle weakness
Early recognition and treatment have dramatically reduced the number of serious complications associated with checkpoint inhibitors.
PeopleBeatingCancer Takeaway
Understanding how Yervoy and Opdivo work can help explain both their remarkable effectiveness and their risks.
Yervoy removes an early immune checkpoint, creating a broad and powerful immune response that can attack cancer—but sometimes healthy tissues as well. Opdivo works later in the immune response, helping activated T-cells continue attacking cancer cells with somewhat greater precision.
For many patients, especially those receiving the combination, the goal is to strike the right balance: activate the immune system enough to control the cancer while recognizing and treating immune-related side effects as early as possible.
This balance is one reason why patients who are informed about potential symptoms—and who communicate promptly with their oncology team—often have the best chance of receiving the full benefit of these groundbreaking therapies.
To learn more:
To prepare for Yervoy–
- Integrative Oncology
- Complementary Cancer Therapies
- Cancer Prehabilitation
- Gut Microbiome and Cancer Side Effects
- Vitamin D and Cancer
Yervoy- Induced side effect
- Chemotherapy-Induced Peripheral Neuropathy
- Chemotherapy-Induced Constipation and Diarrhea
- Hand-Foot Syndrome (contrast with taxane neuropathy)
- Chemotherapy-induced Skin Damage
- Chemotherapy-induced hearing loss
- Chemotherapy-induced Cardiomyopathy
- Chemotherapy-induced Fatigue
- Chemotherapy-Induced Anemia
- Enhance Blood Counts Naturally
- Electrolyte Disorders During Chemotherapy
- Exercise During Chemotherapy
- Anti-Inflammatory Diet for Cancer Patients
- Managing Cancer Treatment Side Effects (hub page)
- Financial Toxicity During Cancer Treatment
Lifestyle Post Therapy
Cancer Specific Hubs-
- Melanoma
- Kidney cancer (renal cell carcinoma)
- Colorectal cancer with MSI-H/dMMR
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Pleural mesothelioma
- Esophageal squamous cell carcinoma
Research References
- Yervoy (ipilimumab) U.S. Prescribing Information. Bristol Myers Squibb.
- FDA Prescribing Information for Yervoy.
- Tarhini A, et al. Immune-Mediated Adverse Events Associated with Ipilimumab Therapy. Oncologist. 2013.
- Hodi FS, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine. 2010.
- Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine. 2015.
- Weber JS, et al. Management of Immune-Related Adverse Events. Journal of Clinical Oncology.
- ASCO Clinical Practice Guideline: Management of Immune-Related Adverse Events.
- Society for Immunotherapy of Cancer (SITC) Clinical Practice Guidelines.
Yervoy (Ipilimumab) for Cancer